



P: 1300 688 522
E: info@nutripath.com.au
A: PO Box 442 Ashburton VIC 3142

TEST PATIENT

GUa d'Y'HYghBUa Y
Sex : :
DUHY Collected : 00-00-0000
111 H9GH ROAD TEST SUBURB
@AB =8: 00000000 UR#:0000000

TEST PHYSICIAN

DR JOHN DOE
111 CLINIC STF 99H
7@B=7 'GI 6I F 6'J =7'' \$\$\$

GENOMIC TESTING

Summary of Results

Propionic Acidemia

Risk to Child: Any child of this patient has a 50% chance of inheriting the patient's mutation associated with this disease and being a carrier. If the patient's partner also carries a mutation for this disease, there is a 25% chance that each child of the patient will inherit both parents' mutations and may develop the disease.

Risk to Patient: This patient is a carrier of a genetic mutation for this disease but is not likely to be affected. Since there are many rare mutations, it is possible to carry an untested mutation in addition to the one found in the patient's DNA.

Recommendation: Genetic counseling is recommended for the patient and his or her partner to discuss the potential clinical and/or reproductive implications of this result and to discuss genetic testing of the patient's partner and close relatives.

Result:

Carrier, Heterozygote

Mutations:

PCCB [c.1228C>T (p.R410W)]

PATIENT IS NOT A CARRIER FOR THE FOLLOWING:

| | | | |
|---|--|--|---|
| 21-Hydroxylase-deficient congenital adrenal hyperplasia | Costeff optic atrophy syndrome | Hereditary fructose intolerance | Pendred syndrome |
| 3-Methylcrotonyl-CoA carboxylase deficiency | Crigler-Najjar syndrome | Herlitz junctional epidermolysis bullosa, LAMA3-related | Phenylketonuria |
| Achromatopsia | Cystic fibrosis | Herlitz junctional epidermolysis bullosa, LAMB3-related | Polycystic kidney disease |
| Acrodermatitis enteropathica | Cystinosis | Herlitz junctional epidermolysis bullosa, LAMC2-related | Pompe disease |
| Alkaptonuria | Diabetes, permanent neonatal | HMG-CoA lyase deficiency | Prekallikrein deficiency |
| Alpha-1 antitrypsin deficiency | Dihydropyrimidine dehydrogenase deficiency | Homocystinuria, cbIE type | Primary hyperoxaluria, type 1 |
| Alpha-mannosidosis | Dubin-Johnson syndrome | Homocystinuria, classic | Primary hyperoxaluria, type 2 |
| Amyotrophic lateral sclerosis | Ehlers-Danlos syndrome, dermatosparaxis | Hurler syndrome | Primary hyperoxaluria, type 3 |
| Andermann syndrome | Ehlers-Danlos syndrome, hypermobility | Hypophosphatasia, autosomal recessive | Prothrombin deficiency |
| Argininosuccinate lyase deficiency | Ehlers-Danlos syndrome, kyphoscoliotic | Inclusion body myopathy 2 | Rh-null syndrome |
| ARSACS | Factor V Leiden thrombophilia | Juvenile retinoschisis, X-linked | Rhizomelic chondrodysplasia punctata type 1 |
| Aspartylglucosaminuria | Factor XI deficiency | Krabbe disease | Rickets, pseudovitamin D-deficiency |
| Ataxia with vitamin E deficiency | Familial dysautonomia | Lipoamide dehydrogenase deficiency | Salla disease |
| Ataxia-telangiectasia | Familial Mediterranean fever | Lipoprotein lipase deficiency, familial | Sandhoff disease |
| Autoimmune polyglandular syndrome, type I | Fanconi anemia | Maple syrup urine disease | Short-chain acyl-CoA dehydrogenase deficiency |
| Bardet-Biedl syndrome, BBS1-related | Galactokinase deficiency | Medium-chain acyl-CoA dehydrogenase deficiency | Sick sinus syndrome |
| Bartter syndrome, type 4a | Galactosemia | Megalencephalic leukoencephalopathy with subcortical cysts | Sickle cell disease |
| Beta-ketothiolase deficiency | Gaucher disease | Metachromatic leukodystrophy | Smith-Lemli-Opitz syndrome |
| Beta-thalassemia | Glutaric acidemia, type 1 | Methylmalonic acidemia | Spherocytosis, hereditary |
| Biotinidase deficiency | Glycogen storage disease, type 1a | Mucopolipidosis II | Tay-Sachs disease |
| Bloom syndrome | Glycogen storage disease, type Ib | Mucopolipidosis III | Tay-Sachs pseudodeficiency |
| Canavan disease | Glycogen storage disease, type III | Mucopolipidosis IV | Thrombocytopenia, congenital amegakaryocytic |

PATIENT IS NOT A CARRIER FOR THE FOLLOWING:

| | | | |
|--|--|--|---|
| Carnitine deficiency, primary systemic | Glycogen storage disease, type V | Multiple carboxylase deficiency | Tyrosine hydroxylase deficiency |
| Carnitine palmitoyltransferase II deficiency | GM1-gangliosidosis | Nephrotic syndrome, steroid-resistant | Tyrosinemia |
| Cartilage-hair hypoplasia | Hearing loss, DFNB1 and DFNB9 nonsyndromic | Neuronal ceroid lipofuscinosis, CLN3-related | Usher syndrome, type 1F |
| Cerebrotendinous xanthomatosis | Hearing loss, DFNB59 nonsyndromic | Neuronal ceroid lipofuscinosis, CLN5-related | Very long-chain acyl-CoA dehydrogenase deficiency |
| Choroideremia | Hemochromatosis | Neuronal ceroid lipofuscinosis, CLN8-related | Von Willebrand disease, type 2 Normandy |
| Citrullinemia, type I | Hemoglobin C | Neuronal ceroid lipofuscinosis, PPT1-related | Von Willebrand disease, type 3 |
| Cohen syndrome | Hemoglobin D | Neuronal ceroid lipofuscinosis, TPP1-related | Wilson disease |
| Combined pituitary hormone deficiency, PROP1-related | Hemoglobin E | Niemann-Pick disease | Zellweger syndrome spectrum, PEX1-related |
| Congenital disorder of glycosylation type Ia | Hemoglobin O | Nijmegen breakage syndrome | |

Propionic Acidemia

About: Propionic acidemia is an inherited disorder that causes brain damage in infants and young children due to a defect in protein and fat metabolism. Symptoms may include poor appetite, nausea, vomiting, extreme sleepiness, irritability, low muscle tone and muscle weakness. If not treated, breathing problems, seizures, swelling of the brain, stroke, coma and sometimes even death can occur. With prompt and lifelong treatment, children with propionic acidemia can often live normal lives. A small number of people with propionic acidemia never show symptoms.¹

Genetics: Propionic acidemia is caused by mutations in the PCCA or the PCCB genes, which encode the alpha and beta protein subunits, respectively, of propionyl-CoA carboxylase. This enzyme is necessary for breaking down certain amino acids (valine, isoleucine, methionine, and threonine) and fats (odd-chain fatty acids, cholesterol).^{2,3} Defects in the protein lead to toxic levels of propionic acid; by-products accumulate in body fluids and can cause brain damage.

The incidence of propionic acidemia is very low worldwide (about 1 in 50,000) but highly variable: 1 in 1,000 in the Inuit people of Greenland. The incidence of propionic acidemia is 1 in 27,264 in Saudi Arabia, and 1 in 250,000 in Germany.⁴

Mutations Tested: The test involves one mutation in the PCCA gene and four mutations in PCCB gene.

PCCA [R3999Q]

PCCB [R410W, T428I, 1218del14ins12, 1172_1173insT]

References

1. Yang X, Sakamoto O, Matsubara Y, et al. Mutation spectrum of the PCCA and PCCB genes in Japanese patients with propionic acidemia. *Molecular genetics and metabolism*. 2004;81:335-42.
2. Ugarte M, Pérez-Cerdá C, Rodríguez-Pombo P, et al. Overview of mutations in the PCCA and PCCB genes causing propionic acidemia. *Human mutation*. 1999;14:275-82.
3. Lamhonwah AM, Troxel CE, Schuster S, Gravel RA. Two distinct mutations at the same site in the PCCB gene in propionic acidemia. *Genomics*. 1990;8:249-54.
4. Desviat LR, Pérez B, Pérez-Cerdá C, et al. Propionic acidemia: mutation update and functional and structural effects of the variant alleles. *Molecular genetics and metabolism*. 2004;83:28-37.

| | |
|-------------|----------------|
| PATIENT ID | SAMPLE PATIENT |
| GENDER | M |
| ACCESSION # | XXXXXXX |
| REPORT DATE | Feb 27, 2017 |

GENOTYPE/HAPLOTYPE DETAIL

CARRIER STATUS

This section lists the individual mutations that were tested for Carrier Status. Tested mutations are organized by disease and contained in brackets next to their respective genes.

- If the patient carries a tested mutation, it will be highlighted in red in the “Carrier of” section.
- If the patient does not carry a tested mutation, it will be listed in black in the “Not a Carrier of” section.
- If a result could not be obtained for a mutation, it is listed in the “No Data for” section.
- “Pending” indicates that the patient’s test for this disease is still in progress.
- “Unable To Report” indicates that no result can be provided.

Residual risk: since there are many rare mutations, it is possible to carry a mutation that is not included in our test.

PROPIONIC ACIDEMIA

Heterozygous for: **PCCB** [c.1228C>T (p.R410W)]
 Not a Carrier of: **PCCA** [c.1196G>A (p.R399Q)]; **PCCB** [c.1173dupT (p.V392CfsX2), c.1283C>T (p.T428I), c.1218_1231delinsTAGAGCACAGGA (p.G407RfsX14)]

21-HYDROXYLASE-DEFICIENT CONGENITAL ADRENAL HYPERPLASIA

Not a Carrier of: **CYP21A2** [c.293-2A>G, c.1360C>T (p.P454S), c.293-13C>G, c.844G>T (p.V282L)/c.844G>C (p.V282L), c.518T>A (p.I173N), c.719T>A (p.M240K), c.955C>T (p.Q319X), c.1069C>T (p.R357W), c.92C>T (p.P31L), c.713T>A (p.V238E), c.923dupT (p.L308FfsX6), c.332_339del (p.G111VfsX21)]

3-METHYLCROTONYL-COA CARBOXYLASE DEFICIENCY

Not a Carrier of: **MCCC1** [c.866C>T (p.A289V), c.1155A>C (p.R385S), c.1594G>C (p.D532H), c.1310T>C (p.L437P)]; **MCCC2** [c.295G>C (p.E99Q), c.1309A>G (p.I437V), c.1015G>A (p.V339M), c.577C>T (p.R193C), c.518C>T (p.S173L)]

ACHROMATOPSIA

Not a Carrier of: **CNGA3** [c.847C>T (p.R283W), c.1641C>A (p.F547L), c.829C>T (p.R277C), c.1306C>T (p.R436W)]; **CNGB3** [c.819_826del

ACHROMATOPSIA

(p.R274VfsX13), c.991-3T>G, c.886_896delinsT (p.T296YfsX9), c.1304C>T (p.S435F), c.1578+1G>A, c.1006G>T (p.E336X), c.1148delC (p.T383IfsX13)]

ACRODERMATITIS ENTEROPATHICA

Not a Carrier of: **SLC39A4** [c.1224_1228del (p.G409LfsX7), c.143T>G (p.L48X)]

ALKAPTONURIA

Not a Carrier of: **HGD** [c.360T>G (p.C120W), c.481G>A (p.G161R), c.1102A>G (p.M368V), c.342+1G>A]

ALPHA-1 ANTITRYPSIN DEFICIENCY

Not a Carrier of: **SERPINA1** [c.863A>T (p.E288V, S allele), c.1096G>A (p.E366K, Z allele)]

ALPHA-MANNOSIDOSIS

Not a Carrier of: **MAN2B1** [c.1830+1G>C, c.2248C>T (p.R750W), c.2426T>C (p.L809P)]

AMYOTROPHIC LATERAL SCLEROSIS

Not a Carrier of: **ALS2** [c.1867_1868del (p.L623Vfs)]

ANDERMANN SYNDROME

Not a Carrier of: **SLC12A6** [c.2032dupT (p.Y678LfsX41), c.3031C>T (p.R1011X), c.2023C>T (p.R675X), c.2436delG (p.T813PfsX2), c.1584_1585delinsG (p.F529LX4), c.1478_1485del (p.F493CfsX48)]

ARGININOSUCCINATE LYASE DEFICIENCY

Not a Carrier of: **ASL** [c.1153C>T (p.R385C), c.532G>A (p.V178M), c.446+1G>A (IVS5+1G>A), c.1060C>T (p.Q354X), c.346C>T (p.Q116X), c.578G>A (p.R193Q), c.260A>G (p.D87G)]

ARSACS

Not a Carrier of: **SACS** [c.8844delT (p.I2949FfsX4), c.7504C>T (p.R2502X), c.10907G>A (p.R3636Q), c.12160C>T (p.Q4054X)]

ASPARTYLGLUCOSAMINURIA

Not a Carrier of: **AGA** [c.488G>C (p.C163S)]

ATAXIA WITH VITAMIN E DEFICIENCY

Not a Carrier of: **TTPA** [c.303T>G (p.H101Q), c.744delA (p.E249NfsX15)]

| | |
|-------------|----------------|
| PATIENT ID | SAMPLE PATIENT |
| GENDER | M |
| ACCESSION # | XXXXXXXX |
| REPORT DATE | Feb 27, 2017 |

ATAXIA-TELANGIECTASIA

Not a Carrier of: ATM

[c.1564_1565del (p.E522IfsX43), c.7010_7011del (p.C2337SfsX35), c.7517_7520del (p.R2506RfsX3), c.7638_7646del (p.R2547_S2549del), c.7886_7890del (p.I2629SfsX25), c.8264_8268del (p.Y2755CfsX12), c.397_398insT (p.N133IfsX8), c.2806_2809dupCTAG (p.E937AfsX33), c.7926A>C (p.R2642S), c.1120C>T (p.Q374X), c.4507C>T (p.Q1503X), c.5908C>T (p.Q1980X), c.5932G>T (p.E1978X), c.7449G>A (p.W2483X), c.8494C>T (p.R2832C), c.4852C>T (p.R1618X), c.8011-2A>C, c.5319+2T>C, c.3576G>A (p.K1192K), c.2251-10T>G, c.4612-12A>G, c.4909+1G>A, c.8201_8211delinsGACCTG (p.M2734RfsX11), c.3245_3247delinsTGAT (p.H1082LfsX14), c.8786+1G>A, c.103C>T (p.R35X), c.7327C>T (p.R2443X), c.6095G>A (p.R2032K)]

AUTOIMMUNE POLYGLANDULAR SYNDROME, TYPE I

Not a Carrier of: AIRE [c.931delT (p.C311fsX376), c.1189delC (p.L397fsX478), c.64_69del (p.V22_D23del), c.653-6_653-4del (p.G218fsX284), c.402delC (p.S135fsX147), c.1249delC (p.L417fsX478), c.966_969dupCCTG (p.L323fsX372), c.1295_1296insAC (p.C434VfsX47), c.1242_1243insA (p.H415fsX422), c.1072C>T (p.Q358X), c.908G>C (p.R303P), c.290T>C (p.L97P), c.1336T>G (p.C446G), c.1400+1G>A (IVS11+1G>A), c.879+1G>A (IVS7+1G>A), c.462A>T (p.P154P, IVS3-2A>T), c.1344delinsTT (p.C449fsX502), c.755C>T (p.P252L), c.769C>T (p.R257X), c.247A>G (p.K83E), c.415C>T (p.R139X), c.682G>T (p.G228W), c.1A>T (p.M1L), c.43C>T (p.R15C), c.47C>T (p.T16M), c.83T>C (p.L28P), c.86T>C (p.L29P), c.232T>C (p.W78R), c.238G>T (p.V80L), c.254A>G (p.Y85C), c.269A>G (p.Y90C), c.278T>G (p.L93R), c.230T>C (p.F77S), c.1616C>T (p.P539L), c.995+5G>T (IVS8+5G>T), c.1163_1164insA (p.M388fsX422), c.1638A>T (p.X546C), c.932G>A (p.C311Y), c.967_979del (p.L323SfsX51), c.1103dupC (p.P370fsX370), c.1513delG (p.A502fsX519), c.607C>T (p.R203X), c.892G>A (p.E298K), c.463+2T>C (IVS3+2T>C)]

BARDET-BIEDL SYNDROME, BBS1-RELATED

Not a Carrier of: BBS1 [c.1169T>G (p.M390R)]

BARTTER SYNDROME, TYPE 4A

Not a Carrier of: BSND [c.139G>A (p.G47R)]

BETA-KETOTHIOLASE DEFICIENCY

Not a Carrier of: ACAT1 [c.149delC (p.T50NfsX7), c.890C>T (p.T297M), c.1163+2T>C (IVS11+2T>C), c.547G>A (p.G183R), c.814C>T (p.Q272X), c.622C>T (p.R208X), c.826+1G>T (IVS8+1G>T), c.455G>C (p.G152A)]

BETA-THALASSEMIA

Not a Carrier of: HBB [c.118C>T (p.Q40X, cd39C>T), c.316-2A>C (IVS2+849A>C)/c.316-2A>G (IVS2+849A>G), c.92+5G>T (IVS1+5G>T), c.-78A>G (-28A>G), c.-137C>G (-87C>G), c.-138C>T (-88C>T), c.315+1G>A (IVS2+1G>A), c.75T>A (p.G25G, cd24T>A), c.92+1G>A (IVS1+1G>A), c.59A>G (p.N20S, Hb Malay), c.52A>T (p.K18X, 17A>T), c.316-197C>T (IVS2+654C>T), c.-79A>G (-29A>G), c.316-106C>G (IVS2+745C>G), c.93-21G>A (IVS1+110G>A), c.25_26del (p.K9VfsX14, cd8-AA), c.27dupG (p.S10VfsX14, cd8/9+G), c.92+6T>C (IVS1+6T>C), c.135delC (p.F46LfsX16, cd44-C), c.126_129del (p.F42LfsX19, 41/42-TTCT)]

BIOTINIDASE DEFICIENCY

Not a Carrier of: BTD [c.511G>A (p.A171T), c.1330G>C (p.D444H), c.98_104delinsTCC (p.C33FfsX36), c.1368A>C (p.Q456H), c.1612C>T (p.R538C)]

BLOOM SYNDROME

Not a Carrier of: BLM [c.1284G>A (p.W428X), c.1701G>A (p.W567X), c.2207_2212delinsTAGATTC (p.Y736LfsX5, blmAsh), c.2407dupT (p.W803fsX), c.2923delC (p.Q975fsX), c.2506_2507del (p.R836fsX),

BLOOM SYNDROME

c.557_559del (p.S186X), c.1933C>T (p.Q645X), c.2695C>T (p.R899X)]

CANAVAN DISEASE

Not a Carrier of: ASPA [c.827_828del (p.C276YfsX9), c.244dupA (p.M82NfsX8, 245insA), c.884T>C (p.F295S), c.327T>G (p.Y109X), c.584T>G (p.M195R), c.854A>C (p.E285A), c.693C>A (p.Y231X), c.914C>A (p.A305E), c.433-2A>G (IVS2-2A>G), c.654C>A (p.C218X), c.838C>T (p.P280S), c.820G>A (p.G274R)]

CARNITINE DEFICIENCY, PRIMARY SYSTEMIC

Not a Carrier of: SLC22A5 [c.653_654insTATGGCCATCAGGTTGGAG (p.T219fsX284), c.12C>G (p.Y4X), c.95A>G (p.N32S), c.1319C>T (p.T440M), c.632A>G (p.Y211C), c.505C>T (p.R169W), c.760C>T (p.R254X), c.136C>T (p.P46S), c.849G>T (p.W283C), c.1403C>G (p.T468R)]

CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY

Not a Carrier of: CPT2 [c.149C>A (p.P50H), c.338C>T (p.S113L), c.1507C>T (p.R503C), c.1646G>A (p.G549D), c.1238_1239del (p.K414TfsX7), c.641T>C (p.M214T)]

CARTILAGE-HAIR HYPOPLASIA

Not a Carrier of: RMRP [g.70A>G]

CEREBROTENDINOUS XANTHOMATOSIS

Not a Carrier of: CYP27A1 [c.1321C>T (p.P441S), c.1151C>T (p.P384L), c.409C>T (p.R137W), c.475C>T (p.Q159X), c.691C>T (p.R231X), c.808C>T (p.R270X), c.850A>T (p.K284X), c.1061A>G (p.D354G), c.1183C>T (p.R395C), c.1420C>T (p.R474W), c.1214G>A (p.R405Q), c.1016C>T (p.T339M), c.1415G>C (p.G472A), c.379C>T (p.R127W), c.646G>C (p.A216P), c.380G>A

| | |
|-------------|----------------|
| PATIENT ID | SAMPLE PATIENT |
| GENDER | M |
| ACCESSION # | XXXXXXXX |
| REPORT DATE | Feb 27, 2017 |

CEREBROTENDINOUS XANTHOMATOSIS

(p.R127Q), c.844+1G>A (IVS4+1G>A), c.1263+1G>A (IVS7+1G>A), c.1213C>T (p.R405W), c.1184+1G>A (IVS6+1G>A), c.1185-1G>T (IVS6-1G>T), c.1202C>G (p.P401R), c.1222G>T (p.E408X), c.1263+5G>T (IVS7+5G>T), c.435G>T (p.G145G), c.446+1G>A (IVS2+1G>A), c.583G>T (p.E195X), c.779G>A (p.W260X), c.1381C>T (p.Q461X)]

CHOROIDEREMIA

Not a Carrier of: **CHM** [c.1609+2dupT]

CITRULLINEMIA, TYPE I

Not a Carrier of: **ASS1** [c.285G>T (p.R95S), c.952delG (p.A318LfsX58), c.568T>G (p.Y190D), c.1034T>G (p.V345G), c.539G>A (p.S180N), c.1168G>A (p.G390R), c.910C>T (p.R304W), c.928A>C (p.K310Q), c.919C>T (p.R307C), c.805G>A (p.V269M), c.257G>A (p.R86H), c.421-2A>G (IVS6-2A>G), c.814C>T (p.R272C), c.571G>A (p.E191K), c.1138C>T (p.Q380X)]

COHEN SYNDROME

Not a Carrier of: **VPS13B** [c.8459T>C (p.I2820T), c.3348_3349del (p.C1117FfsX8), c.9259_9260insT (p.L3087FfsX20)]

COMBINED PITUITARY HORMONE DEFICIENCY, PROP1-RELATED

Not a Carrier of: **PROP1** [c.301_302del (p.L102CfsX8)]

CONGENITAL DISORDER OF GLYCOSYLATION TYPE IA

Not a Carrier of: **PMM2** [c.422G>A (p.R141H), c.357C>A (p.F119L)]

COSTEFF OPTIC ATROPHY SYNDROME

Not a Carrier of: **OPA3** [c.415C>T (p.Q139X), c.143-1G>C, c.320_337del (p.Q108_E113del)]

CRIGLER-NAJJAR SYNDROME

Not a Carrier of: **UGT1A1** [c.722_723delAG (p.Q239fsX256), c.517delC (p.H173MfsX32), c.1043delA (p.N348TfsX18), c.1186delG (p.D396IfsX16), c.801delC (p.I268SfsX98), c.396_401del (p.H132_K134delinsQ), c.973delG (p.A325LfsX41), c.652dupT (p.S218FfsX40), c.1223dupG (p.A409SfsX13), c.1127A>G (p.H376R), c.1130G>T (p.G377V), c.1448G>A (p.W483X, TAG), c.1449G>A (p.W483X, TGA), c.101C>A (p.P34Q), c.576C>G (p.Y192X), c.1433C>A (p.A478D), c.554A>C (p.Q185P), c.118T>C (p.W40R), c.1477G>C (p.G493R), c.610A>G (p.M204V), c.847C>T (p.Q283X), c.392T>C (p.L131P), c.875C>T (p.A292V), c.1005G>A (p.W335X), c.1305-1G>A (IVS4-1G>A), c.1304+1G>T (IVS4+1G>T), c.864+1G>C (IVS1+1G>C), c.1085-2A>G (IVS3-2A>G), c.877_890delinsA (p.Y293MfsX69), c.1160_1161delinsGT (p.P387R), c.1198A>G (p.N400D), c.1456T>G (p.Y486D), c.674T>G (p.V225G), c.115C>G (p.H39D), c.222C>A (p.Y74X), c.524T>A (p.L175Q), c.529T>C (p.C177R), c.625C>T (p.R209W), c.698T>G (p.L233R), c.881T>C (p.I294T), c.992A>G (p.Q331R), c.1021C>T (p.R341X), c.1069C>T (p.Q357X), c.1070A>G (p.Q357R), c.1102G>A (p.A368T), c.1124C>T (p.S375F), c.1143C>G (p.S381R), c.1201G>C (p.A401P), c.1282A>G (p.K428E), c.1309A>T (p.K437X), c.1388A>C (p.E463A), c.1463C>T (p.S488F), c.991C>T (p.Q331X), c.1006C>T (p.R336W), c.840C>A (p.C280X), c.513_515del (p.F170del), c.835A>T (p.N279Y), c.1220delA (p.K407RfsX5), c.479T>A (p.V160E), c.1108A>G (p.I370V), c.1328T>C (p.L443P), c.1207C>T (p.R403C)]

CYSTIC FIBROSIS

Not a Carrier of: **CFTR** [c.3659delC (p.T1220KfsX8, 3791delC), c.3773dupT (p.L1258FfsX7, 3905insT), c.3302T>A (p.M1101K), c.1210-11T>G (5T), c.273+3A>C (405+3A>C), c.3752G>A (p.S1251N), c.1364C>A (p.A455E), c.1657C>T (p.R553X), c.3484C>T (p.R1162X), c.3718-2477C>T (3849+10kbC>T), c.2988+1G>A (3120+1G>A), c.2128A>T (p.K710X), c.1652G>A (p.G551D), c.3454G>C (p.D1152H), c.254G>A (p.G85E), c.3140-26A>G (3272-26A>G), c.1585-1G>A (1717-1G>A), c.3846G>A

CYSTIC FIBROSIS

(p.W1282X), c.1477C>T (p.Q493X), c.579+1G>T (711+1G>T), c.1558G>T (p.V520F), c.1040G>C (p.R347P), c.350G>A (p.R117H), c.489+1G>T (621+1G>T), c.3266G>A (p.W1089X), c.1090T>C (p.S364P), c.988G>T (p.G330X), c.3472C>T (p.R1158X), c.3909C>G (p.N1303K), c.1679G>C (p.R560T), c.2657+5G>A (2789+5G>A), c.532G>A (p.G178R), c.1624G>T (p.G542X), c.1521_1523delCTT (p.F508del), c.948delT (p.F316LfsX12, 1078delT), c.1519_1521delATC (p.I507del), c.2052delA (p.K684NfsX38, 2184delA), c.3528delC (p.K1177SfsX15, 3659delC), c.1766+1G>A (1898+1G>A), c.617T>G (p.L206W), c.1055G>A (p.R352Q), c.1572C>A (p.C524X), c.1646G>A (p.S549N), c.1645A>C (p.S549R), c.1721C>A (p.P574H), c.1865G>A (p.G622D), c.2125C>T (p.R709X), c.3587C>G (p.S1196X), c.3612G>A (p.W1204X), c.3712C>T (p.Q1238X), c.935_937del (p.F312del, deltaF311), c.262_263del (p.L88IfsX22, 394delTT), c.442delA (p.I184LfsX5, 574delA), c.531delT (p.I177MfsX12, 663delT), c.803delA (p.N268IfsX17, 935delA), c.805_806del (p.I269PfsX4, 936delTA), c.1545_1546del (p.Y515X, 1677delTA), c.1817_1900del (p.M607_Q634del, 1949del84), c.1911delG (p.Q637HfsX26, 2043delG), c.1923_1931delinsA (p.S641RfsX5, 2055del9>A), c.1973_1985delinsAGAAA (p.R658KfsX4, 2105del13ins5), c.3039delC (p.Y1014TfsX9, 3171delC), c.3744delA (p.K1250RfsX9, 3876delA), c.2175dupA (p.E726RfsX4, 2307insA), c.2737_2738insG (p.Y913X, 2869insG), c.273+1G>A (405+1G>A), c.580-1G>T (712-1G>T), c.1680-1G>A (1812-1G>A), c.2988G>A (p.Q996Q, 3120G>A), c.313delA (p.I105SfsX2, 444delA), c.613C>T (p.P205S), c.1976delA (p.N659IfsX4), c.1647T>G (p.S549R), c.1000C>T (p.R334W), c.1682C>A (p.A561E), c.2249C>T (p.P750L), c.1673T>C (p.L558S), c.4046G>A (p.G1349D), c.3532_3535dupTCAA (p.T1179IfsX17, 3667ins4), c.1075_1079delinsAAAAA (p.Q359_T360delinsKK, Q359K/T360K), c.3299A>C (p.Q1100P), c.695T>A (p.V232D), c.714delT (p.L240X)]

CYSTINOSIS

Not a Carrier of: **CTNS** [c.18_21del (p.T7FfsX7), c.614_616del (p.D205del), 57-kb deletion,

| | |
|-------------|----------------|
| PATIENT ID | SAMPLE PATIENT |
| GENDER | M |
| ACCESSION # | XXXXXXXX |
| REPORT DATE | Feb 27, 2017 |

CYSTINOSIS

c.382C>T (p.Q128X), c.544T>C (p.W182R), c.922G>A (p.G308R), c.397A>T (p.I133F), c.414G>A (p.W138X), c.473T>C (p.L158P)]

DIABETES, PERMANENT NEONATAL

Not a Carrier of: **ABCC8** [c.215A>G (p.N72S), c.1144G>A (p.E382K), c.134C>T (p.P45L)]; **GCK** [c.1190G>T (p.R397L), c.1019+2T>G (IVS8+2T>G)]

DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY

Not a Carrier of: **DPYD** [c.1339+1G>T (IVS11+1G>T), c.703C>T (p.R235W), c.2657G>A (p.R886H), c.1905+1G>A (IVS14+1G>A), c.1679T>G (p.I560S), c.2933A>G (p.H978R), c.1003G>T (p.V335L), c.1156G>T (p.E386X), c.257C>T (p.P86L), c.2329G>T (p.A777S), c.545T>A (p.M182K)]

DUBIN-JOHNSON SYNDROME

Not a Carrier of: **ABCC2** [c.3449G>A (p.R1150H), c.3517A>T (p.I1173F)]

EHLERS-DANLOS SYNDROME, DERMATOSPARAXIS

Not a Carrier of: **ADAMTS2** [c.673C>T (p.Q225X), c.2384G>A (p.W795X)]

EHLERS-DANLOS SYNDROME, HYPERMOBILITY

Not a Carrier of: **TNXB** [c.2116_2117dupGT (p.E707X), c.3290_3291del (p.K1097RfsX48, 3551_3552delAA)]

EHLERS-DANLOS SYNDROME, KYPHOSCOLIOTIC

Not a Carrier of: **PLOD1** [c.1362delC (p.Y455TfsX2), c.467-2delA, c.1677dupC (p.I560HfsX8, 1702insC), c.975+2_975+3insTT, c.153dupC (p.N52QfsX52), c.426T>A (p.Y142X), c.979C>T (p.Q327X), c.145C>T (p.Q49X), c.1336T>G (p.W446G), c.2117A>G (p.H706R), c.955C>T (p.R319X), c.2032G>A (p.G678R),

EHLERS-DANLOS SYNDROME, KYPHOSCOLIOTIC

c.1533C>G (p.Y511X), c.1836G>C (p.W612C), c.2008C>T (p.R670X), c.1999G>A (p.A667T)]

FACTOR V LEIDEN THROMBOPHILIA

Not a Carrier of: **F5** [c.1601G>A (p.R534Q, Factor V Leiden)]

FACTOR XI DEFICIENCY

Not a Carrier of: **F11** [c.403G>T (p.E135X), c.901T>C (p.F301L), c.438C>A (p.C146X), c.1716+1G>A (IVS14+1G>A)]

FAMILIAL DYSAUTONOMIA

Not a Carrier of: **IKBKAP** [c.2204+6T>C (IVS20+6T>C), c.2087G>C (p.R696P)]

FAMILIAL MEDITERRANEAN FEVER

Not a Carrier of: **MEFV** [c.2082G>A (p.M694I), c.2177T>C (p.V726A), c.2040G>C (p.M680I), c.2230G>T (p.A744S), c.2080A>G (p.M694V), c.1958G>A (p.R653H), c.2084A>G (p.K695R), c.2282G>A (p.R761H)]

FANCONI ANEMIA

Not a Carrier of: **FANCC** [c.456+4A>T (IVS4+4A>T), c.1642C>T (p.R548X), c.1661T>C (p.L554P), c.67delG (p.D23IfsX23, 322delG), c.553C>T (p.R185X), c.37C>T (p.Q13X)]

GALACTOKINASE DEFICIENCY

Not a Carrier of: **GALK1** [c.1144C>T (p.Q382X), c.1031C>T (p.T344M), c.766C>T (p.R256W), c.1045G>A (p.G349S)]

GALACTOSEMIA

Not a Carrier of: **GALT** [c.652C>G (p.L218V), c.940A>G (p.N314D), c.563A>G (p.Q188R), c.-119_-116del, c.253-2A>G (IVS2-2A>G), c.404C>T (p.S135L), c.512T>C (p.F171S),

GALACTOSEMIA

c.584T>C (p.L195P), c.607G>A (p.E203K), c.626A>G (p.Y209C), c.855G>T (p.K285N)]

GAUCHER DISEASE

Not a Carrier of: **GBA** [c.1488T>C (p.L483P, L444P), c.1342G>C (p.D448H, D409H), c.1604G>A (p.R535H), c.1226A>G (p.N409S, N370S), c.1297G>T (p.V433L, V394L), c.1504C>T (p.R502C, R463C), c.115+1G>A (IVS2+1G>A), c.84dupG (p.L29AfsX18)]

GLUTARIC ACIDEMIA, TYPE 1

Not a Carrier of: **GCDH** [c.1262C>T (p.A421V), c.1204C>T (p.R402W), c.877G>A (p.A293T), c.1198G>A (p.V400M), c.680G>C (p.R227P)]

GLYCOGEN STORAGE DISEASE, TYPE 1A

Not a Carrier of: **G6PC** [c.247C>T (p.R83C), c.248G>A (p.R83H), c.79delC (p.Q27RfsX9), c.562G>C (p.G188R), c.809G>T (p.G270V), c.724C>T (p.Q242X), c.980_982del (p.F327del), c.1039C>T (p.Q347X), c.379_380dupTA (p.Y128TfsX3)]

GLYCOGEN STORAGE DISEASE, TYPE IB

Not a Carrier of: **SLC37A4** [c.1042_1043del (p.L348VfsX53), c.1015G>T (p.G339C), c.352T>C (p.W118R)]

GLYCOGEN STORAGE DISEASE, TYPE III

Not a Carrier of: **AGL** [c.2590C>T (p.R864X), c.3682C>T (p.R1228X), c.3965delT (p.V1322AfsX27), c.4260-12A>G (IVS32-12A>G)]

GLYCOGEN STORAGE DISEASE, TYPE V

Not a Carrier of: **PYGM** [c.148C>T (p.R50X), c.613G>A (p.G205S)]

| | |
|-------------|----------------|
| PATIENT ID | SAMPLE PATIENT |
| GENDER | M |
| ACCESSION # | XXXXXXXX |
| REPORT DATE | Feb 27, 2017 |

GM1-GANGLIOSIDOSIS

Not a Carrier of: **GLB1** [c.176G>A (p.R59H)]

HEARING LOSS, DFNB1 AND DFNB9 NONSYNDROMIC

Not a Carrier of: **GJB2** [c.377_378insATGCGGA (p.R127CfsX85), c.439G>A (p.E147K), c.109G>A (p.V37I), c.35delG (p.G12VfsX2), c.-23+1G>A, c.167delT (p.L56RfsX26), c.235delC (p.L79CfsX3), c.231G>A (p.W77X), c.269T>C (p.L90P), c.71G>A (p.W24X), c.299_300del (p.H100RfsX14), c.1A>G (p.M1V), c.283G>A (p.V95M), c.370C>T (p.Q124X)]; **OTOF** [c.2485C>T (p.Q829X)]

HEARING LOSS, DFNB59 NONSYNDROMIC

Not a Carrier of: **DFNB59** [c.509_512del (p.S170CfsX37), c.726delT (p.F242LfsX7), c.988delG (p.V330LfsX7), c.113dupT (p.K41EfsX8), c.499C>T (p.R167X), c.731T>G (p.L244R)]

HEMOCHROMATOSIS

Not a Carrier of: **HFE** [c.845G>A (p.C282Y), c.187C>G (p.H63D), c.193A>T (p.S65C)]; **HFE2** [c.959G>T (p.G320V)]; **TFR2** [c.515T>A (p.M172K), c.750C>G (p.Y250X)]

HEMOGLOBIN C

Not a Carrier of: **HBB** [c.19G>A (p.E7K, Hemoglobin C)]

HEMOGLOBIN D

Not a Carrier of: **HBB** [c.364G>C (p.E122Q, Hemoglobin D-Punjab)]

HEMOGLOBIN E

Not a Carrier of: **HBB** [c.79G>A (p.E27K, Hemoglobin E)]

HEMOGLOBIN O

Not a Carrier of: **HBB** [c.364G>A (p.E122K, Hemoglobin O)]

HEREDITARY FRUCTOSE INTOLERANCE

Not a Carrier of: **ALDOB** [c.448G>C (p.A150P), c.524C>A (p.A175D), c.1005C>G (p.N335K), c.612T>A (p.Y204X)/c.612T>G (p.Y204X), c.360_363del (p.N120KfsX32)]

HERLITZ JUNCTIONAL EPIDERMOLYSIS BULLOSA, LAMA3-RELATED

Not a Carrier of: **LAMA3** [c.1981C>T (p.R661X)]

HERLITZ JUNCTIONAL EPIDERMOLYSIS BULLOSA, LAMB3-RELATED

Not a Carrier of: **LAMB3** [c.958_1034dup (p.N345KfsX77, 957ins77), c.124C>T (p.R42X), c.727C>T (p.Q243X), c.1903C>T (p.R635X)]

HERLITZ JUNCTIONAL EPIDERMOLYSIS BULLOSA, LAMC2-RELATED

Not a Carrier of: **LAMC2** [c.283C>T (p.R95X)]

HMG-COA LYASE DEFICIENCY

Not a Carrier of: **HMGCL** [c.505_506del (p.S169LfsX8, 504_505delCT), c.122G>A (p.R41Q), c.109G>T (p.E37X)]

HOMOCYSTINURIA, CBLE TYPE

Not a Carrier of: **MTRR** [c.1953-6_1953-2del, c.1728_1730del (p.L576del, 1726delTTG), c.1622_1623dupTA (p.M542X), c.7A>T (p.R3W), c.1573C>T (p.R525X)]

HOMOCYSTINURIA, CLASSIC

Not a Carrier of: **CBS** [c.1591_1594del (p.F531GfsX9), c.892dupC (p.Q298PfsX32), c.1619_1622dupTGAA (p.F542EfsX37), c.1046G>A (p.S349N), c.676G>A (p.A226T), c.1126G>A (p.D376N), c.464C>T (p.A155V), c.503T>C

HOMOCYSTINURIA, CLASSIC

(p.V168A), c.694C>G (p.H232D), c.650C>T (p.S217F), c.129G>A (p.W43X), c.141T>A (p.D47E), c.969G>A (p.W323X), c.715G>A (p.E239K), c.262C>T (p.P88S), c.494G>A (p.C165Y), c.526G>A (p.E176K), c.384G>C (p.E128D), c.1063G>C (p.A355P), c.253G>A (p.G85R), c.376A>G (p.M126V), c.796A>G (p.R266G), c.1304T>C (p.I435T), c.1471C>T (p.R491C), c.1039+1G>T (IVS9+1G>T), c.828+1G>A (IVS7+1G>A), c.954+1G>A (IVS8+1G>A), c.833T>C (p.I278T), c.1106G>A (p.R369H), c.1330G>A (p.D444N), c.1105C>T (p.R369C), c.919G>A (p.G307S), c.434C>T (p.P145L), c.341C>T (p.A114V), c.415G>A (p.G139R), c.430G>A (p.E144K), c.1150A>G (p.K384E), c.1616T>C (p.L539S), c.797G>A (p.R266K), c.1397C>T (p.S466L), c.1058C>T (p.T353M), c.572C>T (p.T191M), c.146C>T (p.P49L), c.1060G>A (p.V354M), c.1111G>A (p.V371M), c.451G>A (p.G151R), c.1224-2A>C (IVS11-2A>C), c.1006C>T (p.R336C), c.172C>T (p.R58W), c.442G>A (p.G148R), c.770C>T (p.T257M), c.346G>A (p.G116R), c.1007G>A (p.R336H), c.869C>T (p.P290L), c.1135C>T (p.R379W), c.1039G>A (p.G347S), c.361C>T (p.R121C), c.325T>C (p.C109R), c.904G>A (p.E302K), c.959T>C (p.V320A), c.1566delG (p.K523SfsX18), c.233C>G (p.P78R), c.306G>C (p.K102N), c.1358+1G>A (IVS12+1G>A), c.302T>C (p.L101P)]

HURLER SYNDROME

Not a Carrier of: **IDUA** [c.1814_1815del (p.F605CfsX53), c.1044_1049del (p.D349_N350del), c.1695_1705del (p.L566GfsX2), c.1205G>A (p.W402X), c.208C>T (p.Q70X)]

HYPOPHOSPHATASIA, AUTOSOMAL RECESSIVE

Not a Carrier of: **ALPL** [c.571G>A (p.E191K), c.1133A>T (p.D378V), c.1001G>A (p.G334D), c.979T>C (p.F327L), c.1559delT (p.L520RfsX86)]

| | |
|-------------|----------------|
| PATIENT ID | SAMPLE PATIENT |
| GENDER | M |
| ACCESSION # | XXXXXXXX |
| REPORT DATE | Feb 27, 2017 |

INCLUSION BODY MYOPATHY 2

Not a Carrier of: **GNE** [c.2228T>C (p.M743T), c.1807G>C (p.V603L)]

JUVENILE RETINOSCHISIS, X-LINKED

Not a Carrier of: **RS1** [c.214G>A (p.E72K), c.221G>T (p.G74V), c.325G>C (p.G109R)]

KRABBE DISEASE

Not a Carrier of: **GALC** [c.857G>A (p.G286D)]

LIPOAMIDE DEHYDROGENASE DEFICIENCY

Not a Carrier of: **DLD** [c.685G>T (p.G229C)]

LIPOPROTEIN LIPASE DEFICIENCY, FAMILIAL

Not a Carrier of: **LPL** [c.644G>A (p.G215E)]

MAPLE SYRUP URINE DISEASE

Not a Carrier of: **BCKDHB** [c.548G>C (p.R183P), c.832G>A (p.G278S), c.1114G>T (p.E372X)]

MEDIUM-CHAIN ACYL-COA DEHYDROGENASE DEFICIENCY

Not a Carrier of: **ACADM** [c.985A>G (p.K329E), c.199T>C (p.Y67H)]

MEGALENCEPHALIC LEUKOENCEPHALOPATHY WITH SUBCORTICAL CYSTS

Not a Carrier of: **HEPACAM** [c.275G>A (p.R92Q)]; **MLC1** [c.298_423+108del, c.135dupC (p.C46LfsX34), c.176G>A (p.G59E), c.178-10T>A, c.278C>T (p.S93L)]

METACHROMATIC LEUKODYSTROPHY

Not a Carrier of: **ARSA** [c.1283C>T (p.P428L), c.293C>T (p.S98F), c.542T>G (p.I181S), c.257G>A (p.R86Q), c.641C>T (p.A214V), c.465+1G>A, c.1210+1G>A, c.1408_1418del (p.A470LfsX99)]

METHYLMALONIC ACIDEMIA

Not a Carrier of: **MMAA** [c.503delC (p.T168MfsX10), c.433C>T (p.R145X)]; **MUT** [c.2150G>T (p.G717V), c.349G>T (p.E117X), c.655A>T (p.N219Y), c.322C>T (p.R108C), c.1105C>T (p.R369C)]

MUCOLIPIDOSIS II

Not a Carrier of: **GNPTAB** [c.3503_3504del (p.L1168QfsX5), c.3613C>T (p.R1205X), c.1581delC (p.C528VfsX19), c.310C>T (p.Q104X), c.3565C>T (p.R1189X), c.2533C>T (p.Q845X), c.616_619del (p.T206YfsX6)]

MUCOLIPIDOSIS III

Not a Carrier of: **GNPTAB** [c.10A>C (p.K4Q), c.3335+6T>G (IVS17+6T>G)]; **GNPTG** [c.499dupC (p.L167PfsX32), c.347_349del (p.N116del)]

MUCOLIPIDOSIS IV

Not a Carrier of: **MCOLN1** [del6.4kb, c.406-2A>G (IVS3-2A>G)]

MULTIPLE CARBOXYLASE DEFICIENCY

Not a Carrier of: **HLCS** [c.710T>C (p.L237P), c.1711G>A (p.D571N), c.1522C>T (p.R508W), c.1741G>A (p.G581S), c.1648G>A (p.V550M), c.1993C>T (p.R665X), c.782delG (p.G261VfsX20, 780delG)]

NEPHROTIC SYNDROME, STEROID-RESISTANT

Not a Carrier of: **NPHS2** [c.436delA (p.R146EfsX35), c.1036delC (p.L346YfsX2), c.413G>A (p.R138Q)]

NEURONAL CEROID LIPOFUSCINOSIS, CLN3-RELATED

Not a Carrier of: **CLN3** [c.461-280_677+382del]

NEURONAL CEROID LIPOFUSCINOSIS, CLN5-RELATED

Not a Carrier of: **CLN5** [c.1175_1176del (p.Y392X)]

NEURONAL CEROID LIPOFUSCINOSIS, CLN8-RELATED

Not a Carrier of: **CLN8** [c.70C>G (p.R24G)]

NEURONAL CEROID LIPOFUSCINOSIS, PPT1-RELATED

Not a Carrier of: **PPT1** [c.364A>T (p.R122W), c.451C>T (p.R151X)]

NEURONAL CEROID LIPOFUSCINOSIS, TPP1-RELATED

Not a Carrier of: **TPP1** [c.509-1G>C, c.622C>T (p.R208X)]

NIEMANN-PICK DISEASE

Not a Carrier of: **NPC1** [c.2974G>T (p.G992W), c.3182T>C (p.I1061T)]; **NPC2** [c.58G>T (p.E20X)]; **SMPD1** [c.1493G>T (p.R498L, R496L), c.1829_1831del (p.R610del, deltaR608), c.911T>C (p.L304P, L302P), c.1267C>T (p.H423Y, H421Y), c.996delC (p.P333SfsX52, P330SfsX382)]

NIJMEGEN BREAKAGE SYNDROME

Not a Carrier of: **NBN** [c.657_661del (p.K219NfsX16)]

| | |
|-------------|----------------|
| PATIENT ID | SAMPLE PATIENT |
| GENDER | M |
| ACCESSION # | XXXXXXXX |
| REPORT DATE | Feb 27, 2017 |

PENDRED SYNDROME

Not a Carrier of: **SLC26A4** [c.1246A>C (p.T416P), c.707T>C (p.L236P), c.1001+1G>A, c.1151A>G (p.E384G), c.716T>A (p.V239D), c.919-2A>G, c.2168A>G (p.H723R), c.1540C>A (p.Q514K)]

PHENYLKETONURIA

Not a Carrier of: **PAH** [c.143T>C (p.L48S), c.473G>A (p.R158Q), c.727C>T (p.R243X), c.782G>A (p.R261Q), c.842C>T (p.P281L), c.1066-11G>A (IVS10-11G>A), c.1208C>T (p.A403V), c.1222C>T (p.R408W), c.1223G>A (p.R408Q), c.1241A>G (p.Y414C), c.728G>A (p.R243Q), c.838G>A (p.E280K), c.442-1G>A (IVS4-1G>A), c.611A>G (IVS6-96A>G), c.1068C>A (p.Y356X)/c.1068C>G (p.Y356X), c.117C>G (p.F39L), c.194T>C (p.I65T), c.734T>C (p.V245A), c.331C>T (p.R111X), c.721C>T (p.R241C), c.1238G>C (p.R413P)]

POLYCYSTIC KIDNEY DISEASE

Not a Carrier of: **PKHD1** [c.8829dupC (p.I2944HfsX6), c.107C>T (p.T36M), c.1486C>T (p.R496X), c.10412T>G (p.V3471G), c.10444C>T (p.R3482C), c.2414C>T (p.P805L), c.9530T>C (p.I3177T), c.10174C>T (p.Q3392X), c.664A>G (p.I222V), c.9689delA (p.D3230VfsX34), c.8870T>C (p.I2957T)]

POMPE DISEASE

Not a Carrier of: **GAA** [c.2741delinsCAG (p.Q914PfsX30), c.1935C>A (p.D645E), c.2560C>T (p.R854X), c.525delT (p.E176RfsX45), c.925G>A (p.G309R)]

PREKALLIKREIN DEFICIENCY

Not a Carrier of: **KLKB1** [c.1205G>A (p.W402X), c.1643G>A (p.C548Y)]

PRIMARY HYPEROXALURIA, TYPE 1

Not a Carrier of: **AGXT** [c.508G>A (p.G170R), c.33dupC (p.K12QfsX156)]

PRIMARY HYPEROXALURIA, TYPE 2

Not a Carrier of: **GRHPR** [c.103delG (p.D35TfsX11), c.403_404+2del]

PRIMARY HYPEROXALURIA, TYPE 3

Not a Carrier of: **HOGA1** [c.700+5G>T, c.944_946del (p.E315del)]

PROTHROMBIN DEFICIENCY

Not a Carrier of: **F2** [c.481G>T (p.D161Y, D118Y), c.787C>T (p.R263C, R220C), c.124C>T (p.R42W, R-2W), c.542G>A (p.C181Y, C138Y), c.940C>T (p.R314C, R271C), c.1054G>A (p.E352K, E309K), c.1499G>A (p.R500Q, R457Q), c.1741C>T (p.R581C, R538C)]

RH-NULL SYNDROME

Not a Carrier of: **RHAG** [c.808G>A (p.V270I)]

RHIZOMELIC CHONDRODYSPLASIA PUNCTATE TYPE 1

Not a Carrier of: **PEX7** [c.875T>A (p.L292X), c.653C>T (p.A218V), c.649G>A (p.G217R)]

RICKETS, PSEUDOVITAMIN D-DEFICIENCY

Not a Carrier of: **CYP27B1** [c.1166G>A (p.R389H), c.262delG (p.V88WfsX71, 958delG), c.589+1G>A (IVS3+1G>A), c.1319_1325dupCCCACCC (p.F443PfsX24, 3398dupCCCACCC)]

SALLA DISEASE

Not a Carrier of: **SLC17A5** [c.115C>T (p.R39C)]

SANDHOFF DISEASE

Not a Carrier of: **HEXB** [c.76delA (p.M26CfsX5), c.445+1G>A (IVS2+1G>A)]

SHORT-CHAIN ACYL-COA DEHYDROGENASE DEFICIENCY

Not a Carrier of: **ACADS** [c.1170C>G (p.I390M), c.1138C>T (p.R380W), c.1058C>T (p.S353L), c.529T>C (p.W177R), c.319C>T (p.R107C), c.136C>T (p.R46W), c.417G>C (p.W139C), c.1095G>T (p.Q365H), c.1108A>G (p.M370V), c.596C>T (p.A199V), c.505A>C (p.T169P)]

SICK SINUS SYNDROME

Not a Carrier of: **SCN5A** [c.3893C>T (p.P1298L), c.659C>T (p.T220I), c.4222G>A (p.G1408R), c.4895G>A (p.R1632H)]

SICKLE CELL DISEASE

Not a Carrier of: **HBB** [c.20A>T (p.E7V, Hemoglobin S)]

SMITH-LEMLI-OPITZ SYNDROME

Not a Carrier of: **DHCR7** [c.452G>A (p.W151X), c.1210C>T (p.R404C), c.278C>T (p.T93M), c.506C>T (p.S169L), c.724C>T (p.R242C), c.725G>A (p.R242H), c.906C>G (p.F302L), c.976G>T (p.V326L), c.1054C>T (p.R352W), c.1228G>A (p.G410S), c.1342G>A (p.E448K), c.832-1G>C (IVS8-1G>C)]

SPHEROCYTOSIS, HEREDITARY

Not a Carrier of: **ANK1** [c.444+16C>T (5703+16C>T), c.1387G>A (p.V463I)]; **EPB42** [c.357G>A (p.W119X), c.424G>A (p.A142T), c.929G>A (p.R310Q), c.523G>T (p.D175Y), c.922+1G>A (IVS6+1G>A), c.949C>T (p.R317C)]

TAY-SACHS DISEASE

Not a Carrier of: **HEXA** [c.613delC (p.L205WfsX2), c.986G>A (p.W329X), c.1003A>T (p.I335F), c.1373G>A (p.C458Y), c.1074-1G>T (IVS9-1G>T), c.533G>A (p.R178H)/c.533G>T (p.R178L), c.1510C>T (p.R504C), c.1073+1G>A (IVS9+1G>A), c.805G>A (p.G269S), c.1496G>A (p.R499H), c.509G>A (p.R170Q), c.915_917del (p.F305del, deltaTTC910-912), c.629C>T (p.S210F), c.508C>T (p.R170W), c.1421+1G>C (IVS12+1G>C), c.571-1G>T (IVS5-1G>T), c.1274_1277dupTATC

| | |
|-------------|----------------|
| PATIENT ID | SAMPLE PATIENT |
| GENDER | M |
| ACCESSION # | XXXXXXXX |
| REPORT DATE | Feb 27, 2017 |

TAY-SACHS DISEASE

(p.Y427IfsX5, 1278insTATC), c.574G>C (p.V192L), c.346+1G>C (IVS2+1G>C)]

TAY-SACHS PSEUDODEFICIENCY

Not a Carrier of: HEXA [c.739C>T (p.R247W), c.745C>T (p.R249W)]

THROMBOCYTOPENIA, CONGENITAL AMEGAKARYOCYTIC

Not a Carrier of: MPL [c.305G>C (p.R102P), c.127C>T (p.R43X)]

TYROSINE HYDROXYLASE DEFICIENCY

Not a Carrier of: TH [c.698G>A (p.R233H), c.707T>C (p.L236P)]

TYROSINEMIA

Not a Carrier of: FAH [c.192G>T (p.Q64H), c.554-1G>T, c.607-6T>G, c.782C>T (p.P261L), c.786G>A (p.W262X), c.1009G>A (p.G337S), c.1062+5G>A]

USHER SYNDROME, TYPE 1F

Not a Carrier of: PCDH15 [c.733C>T (p.R245X)]

VERY LONG-CHAIN ACYL-COA DEHYDROGENASE DEFICIENCY

Not a Carrier of: ACADVL [c.848T>C (p.V283A)]

VON WILLEBRAND DISEASE, TYPE 2 NORMANDY

Not a Carrier of: VWF [c.2311A>G (p.M771V), c.2561G>A (p.R854Q), c.2451T>A (p.H817Q), c.2287A>G (p.R763G), c.2344C>T (p.R782W), c.2354G>A (p.G785E), c.2359G>A (p.E787K), c.2362T>C (p.C788R), c.2363G>A (p.C788Y), c.2372C>T (p.T791M), c.2384A>G (p.Y795C), c.2635G>A (p.D879N), c.3159G>T (p.Q1053H), c.3178T>C (p.C1060R),

VON WILLEBRAND DISEASE, TYPE 2 NORMANDY

c.2411G>T (p.C804F), c.2435C>T (p.P812L), c.2447G>A (p.R816Q), c.2446C>T (p.R816W), c.3232G>A (p.E1078K), c.3673T>G (p.C1225G)]

VON WILLEBRAND DISEASE, TYPE 3

Not a Carrier of: VWF [c.3940delG (p.V1314SfsX34), c.1384delG (p.A462QfsX15), c.3258_3259insT (p.D1087X), c.3736_3737dupCC (p.P1247LfsX7), c.4324_4331dupAGTGTGGA (p.D1444EfsX84), c.7172_7173insT (p.E2391DfsX3), c.1693C>T (p.Q565X), c.3800T>A (p.L1267X), c.2016_2019del (p.S673TfsX67), c.2269_2270del (p.L757VfsX22), c.3943C>T (p.R1315C), c.4036C>T (p.Q1346X), c.4092_4093del (p.L1365VfsX11), c.4368C>A (p.Y1456X), c.5053+1G>A (IVS28+1G>A), c.5170+10C>T (IVS29+10C>T), c.5557C>T (p.R1853X), c.6182delT (p.F2061SfsX38), c.6520T>G (p.C2174G), c.6977-1G>C (IVS40-1G>C), c.7085G>T (p.C2362F), c.7603C>T (p.R2535X), c.7630C>T (p.Q2544X), c.7683delT (p.Q2562SfsX2), c.7729+7C>T (IVS45+7C>T), c.8012G>A (p.C2671Y), c.8155+3G>T (IVS50+3G>T), c.8216G>A (p.C2739Y), c.8262T>G (p.C2754W), c.139G>C (p.D47H), c.276delT (p.F92LfsX11), c.817C>T (p.R273W), c.970C>T (p.R324X), c.1071C>A (p.Y357X), c.1093C>T (p.R365X), c.1110-1G>A (IVS9-1G>A), c.1830C>A (p.Y610X), c.1858G>T (p.E620X), c.191delG (p.G64AfsX19), c.212C>A (p.S71X), c.652C>T (p.Q218X), c.666G>A (p.W222X), c.1117C>T (p.R373X), c.1131G>T (p.W377C), c.2157delA (p.D720TfsX21), c.7300C>T (p.R2434X), c.374_387del (p.G125VfsX3), c.874+1G>A (IVS7+1G>A), c.893dupG (p.M299YfsX4), c.1657dupT (p.W553LfsX97), c.3212G>T (p.C1071F), c.4626C>G (p.Y1542X), c.7139dupT (p.L2380FfsX11), c.7674dupC (p.S2559LfsX8), c.8411G>A (p.C2804Y)]

WILSON DISEASE

Not a Carrier of: ATP7B [c.2333G>T (p.R778L), c.3207C>A (p.H1069Q)]

ZELLWEGER SYNDROME SPECTRUM, PEX1-RELATED

Not a Carrier of: PEX1 [c.2097dupT (p.I700YfsX42), c.2528G>A (p.G843D)]

| | |
|-------------|----------------|
| PATIENT ID | SAMPLE PATIENT |
| GENDER | M |
| ACCESSION # | XXXXXXXX |
| REPORT DATE | Feb 27, 2017 |

RESIDUAL RISK AFTER NEGATIVE TEST RESULTS

21-HYDROXYLASE-DEFICIENT CONGENITAL ADRENAL HYPERPLASIA

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|---------------|--------------|----------------|---------------|
| Yupik Eskimos | 1:9 | 100.0% | Negligible |
| General | 1:60 | 69.0% | 1:191 |

3-METHYLCROTONYL-COA CARBOXYLASE DEFICIENCY

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|--------------------|--------------|----------------|---------------|
| German and Turkish | 1:146 | 4.0% | 1:151 |

ACHROMATOPSIA

CNGB3

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|-------------|--------------|----------------|---------------|
| Pingelapese | 1:3 | 100.0% | Negligible |
| European | 1:91 | 91.0% | 1:1001 |

CNGA3

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------|--------------|----------------|---------------|
| European | 1:181 | 42.0% | 1:311 |

ACRODERMATITIS ENTEROPATHICA

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------|--------------|----------------|---------------|
| Tunisian | 1:500 | 78.0% | 1:2269 |

ALKAPTONURIA

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|--------------------------------|--------------|----------------|---------------|
| Czech, Slovak | 1:90 | 50.0% | 1:179 |
| European (non-Slovak or Czech) | 1:250 | 11.0% | 1:281 |

ALPHA-1 ANTITRYPSIN DEFICIENCY

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|-------------------------------|--------------|----------------|---------------|
| Southern European | 1:7 | 95.0% | 1:121 |
| North American | 1:12 | 95.0% | 1:221 |
| African | 1:14 | 95.0% | 1:261 |
| Northern European | 1:15 | 95.0% | 1:281 |
| Middle East and North African | 1:16 | 95.0% | 1:301 |
| Southeast Asian | 1:84 | 95.0% | 1:1661 |
| Far East Asian | 1:570 | 95.0% | 1:11381 |

ALPHA-MANNOSIDOSIS

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------|--------------|----------------|---------------|
| Pan-ethnic | 1:354 | 35.0% | 1:544 |

AMYOTROPHIC LATERAL SCLEROSIS

DATA NOT AVAILABLE

There is insufficient published data to determine the carrier rate, detection rate, and residual risk for this condition.

ANDERMANN SYNDROME

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|-----------------|--------------|----------------|---------------|
| French-Canadian | 1:23 | 100.0% | Negligible |

ARGININOSUCCINATE LYASE DEFICIENCY

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------|--------------|----------------|---------------|
| Pan-ethnic | 1:194 | 50.0% | 1:387 |

ARSACS

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|-----------------|--------------|----------------|---------------|
| French-Canadian | 1:21 | 96.0% | 1:501 |

| | |
|-------------|----------------|
| PATIENT ID | SAMPLE PATIENT |
| GENDER | M |
| ACCESSION # | XXXXXXXX |
| REPORT DATE | Feb 27, 2017 |

ASPARTYLGLUCOSAMINURIA

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------|--------------|----------------|---------------|
| Finnish | 1:68 | 98.0% | 1:3351 |

ATAXIA WITH VITAMIN E DEFICIENCY

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------------------------|--------------|----------------|---------------|
| Mediterranean, North African | 1:274 | 80.0% | 1:1366 |

ATAXIA-TELANGIECTASIA

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|----------------------|--------------|----------------|---------------|
| Amish | 1:100 | 100.0% | Negligible |
| Costa Rican | 1:100 | 86.0% | 1:708 |
| North African Jewish | 1:100 | 100.0% | Negligible |
| Norwegian | 1:100 | 55.0% | 1:221 |
| Polish | 1:100 | 39.0% | 1:163 |
| Sardinian | 1:100 | 95.0% | 1:1981 |
| Turkish | 1:100 | 33.0% | 1:149 |

AUTOIMMUNE POLYGLANDULAR SYNDROME, TYPE I

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|----------------|--------------|----------------|---------------|
| Iranian Jewish | 1:48 | 100.0% | Negligible |
| Finnish | 1:80 | 71.0% | 1:273 |
| Slovenian | 1:104 | 67.0% | 1:313 |
| Norwegian | 1:150 | 48.0% | 1:288 |
| Polish | 1:250 | 71.0% | 1:860 |

BARDET-BIEDL SYNDROME, BBS1-RELATED

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|--------------------------|--------------|----------------|---------------|
| North American, European | 1:387 | 79.0% | 1:1839 |

BARTTER SYNDROME, TYPE 4A

DATA NOT AVAILABLE

There is insufficient published data to determine the carrier rate, detection rate, and residual risk for this condition.

BETA-KETOTHIOLASE DEFICIENCY

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------|--------------|----------------|---------------|
| Vietnamese | 1:500 | 88.0% | 1:4159 |

BETA-THALASSEMIA

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|----------------|--------------|----------------|---------------|
| Mediterranean | 1:7 | 91.0% | 1:68 |
| Thai | 1:11 | 91.0% | 1:112 |
| West African | 1:11 | 75.0% | 1:41 |
| Middle Eastern | 1:49 | 91.0% | 1:534 |
| Chinese | 1:100 | 91.0% | 1:1101 |

BIOTINIDASE DEFICIENCY

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------|--------------|----------------|---------------|
| Pan-ethnic | 1:120 | 89.0% | 1:1083 |

BLOOM SYNDROME

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------------|--------------|----------------|---------------|
| Ashkenazi Jewish | 1:107 | 99.0% | 1:10601 |

CANAVAN DISEASE

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------------|--------------|----------------|---------------|
| Ashkenazi Jewish | 1:41 | 97.0% | 1:1540 |

CARNITINE DEFICIENCY, PRIMARY SYSTEMIC

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------|--------------|----------------|---------------|
| Taiwanese | 1:1000 | 35.0% | 1:153 |

CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY

DATA NOT AVAILABLE

There is insufficient published data to determine the carrier rate, detection rate, and residual risk for this condition.

CARTILAGE-HAIR HYPOPLASIA

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|-----------------|--------------|----------------|---------------|
| Old Order Amish | 1:10 | 100.0% | Negligible |
| Finnish | 1:76 | 92.0% | 1:939 |

CEREBROTENDINOUS XANTHOMATOSIS

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|----------------------|--------------|----------------|---------------|
| North African Jewish | 1:5 | 79.0% | 1:20 |
| Dutch | 1:111 | 100.0% | Negligible |

CHOROIDEREMIA

DATA NOT AVAILABLE

There is insufficient published data to determine the carrier rate, detection rate, and residual risk for this condition.

| | |
|-------------|----------------|
| PATIENT ID | SAMPLE PATIENT |
| GENDER | M |
| ACCESSION # | XXXXXXXX |
| REPORT DATE | Feb 27, 2017 |

CITRULLINEMIA, TYPE I

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------|--------------|----------------|---------------|
| Pan-ethnic | 1:119 | 46.0% | 1:220 |

COHEN SYNDROME

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|-----------------|--------------|----------------|---------------|
| Old Order Amish | 1:11 | 99.0% | 1:1001 |

COMBINED PITUITARY HORMONE DEFICIENCY, PROP1-RELATED

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------|--------------|----------------|---------------|
| Worldwide | 1:63 | 55.0% | 1:139 |

CONGENITAL DISORDER OF GLYCOSYLATION TYPE IA

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------|--------------|----------------|---------------|
| Danish | 1:60 | 88.0% | 1:493 |

COSTEFF OPTIC ATROPHY SYNDROME

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|--------------|--------------|----------------|---------------|
| Iraqi Jewish | 1:10 | 100.0% | Negligible |

CRIGLER-NAJJAR SYNDROME

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------|--------------|----------------|---------------|
| Caucasian | 1:500 | 75.0% | 1:1997 |

CYSTIC FIBROSIS

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------------------|--------------|----------------|---------------|
| Ashkenazi Jewish | 1:24 | 94.0% | 1:384 |
| Non-Hispanic Caucasian | 1:25 | 88.0% | 1:206 |
| Hispanic Caucasian | 1:58 | 72.0% | 1:205 |
| African American | 1:61 | 64.0% | 1:171 |
| Asian American | 1:94 | 49.0% | 1:183 |

CYSTINOSIS

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|-------------------------------|--------------|----------------|---------------|
| US general, Northern European | 1:158 | 50.0% | 1:315 |

DIABETES, PERMANENT NEONATAL

| | | | |
|---|--|--|--|
| DATA NOT AVAILABLE | | | |
| There is insufficient published data to determine the carrier rate, detection rate, and residual risk for this condition. | | | |

DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------|--------------|----------------|---------------|
| Caucasian | 1:56 | 52.0% | 1:116 |

DUBIN-JOHNSON SYNDROME

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|-----------------|--------------|----------------|---------------|
| Iranian Jewish | 1:18 | 100.0% | Negligible |
| Moroccan Jewish | 1:18 | 100.0% | Negligible |

EHLERS-DANLOS SYNDROME, DERMATOSPARAXIS

| | | | |
|---|--|--|--|
| DATA NOT AVAILABLE | | | |
| There is insufficient published data to determine the carrier rate, detection rate, and residual risk for this condition. | | | |

EHLERS-DANLOS SYNDROME, HYPERMOBILITY

| | | | |
|---|--|--|--|
| DATA NOT AVAILABLE | | | |
| There is insufficient published data to determine the carrier rate, detection rate, and residual risk for this condition. | | | |

EHLERS-DANLOS SYNDROME, KYPHOSCOLIOTIC

| | | | |
|---|--|--|--|
| DATA NOT AVAILABLE | | | |
| There is insufficient published data to determine the carrier rate, detection rate, and residual risk for this condition. | | | |

FACTOR V LEIDEN THROMBOPHILIA

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|-------------------|--------------|----------------|---------------|
| European American | 1:18 | 100.0% | 0 |
| Hispanic American | 1:45 | 100.0% | 0 |
| Native American | 1:80 | 100.0% | 0 |
| African American | 1:83 | 100.0% | 0 |
| Asian American | 1:222 | 100.0% | 0 |

FACTOR XI DEFICIENCY

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------------|--------------|----------------|---------------|
| Ashkenazi Jewish | 1:11 | 98.0% | 1:501 |
| U.K. Pan-ethnic | 1:500 | 39.0% | 1:819 |

FAMILIAL DYSAUTONOMIA

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------------|--------------|----------------|---------------|
| Ashkenazi Jewish | 1:31 | 99.0% | 1:3001 |

| | |
|-------------|----------------|
| PATIENT ID | SAMPLE PATIENT |
| GENDER | M |
| ACCESSION # | H1420485 |
| REPORT DATE | Feb 27, 2017 |

FAMILIAL MEDITERRANEAN FEVER

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|----------------------|--------------|----------------|---------------|
| Armenian | 1:3 | 79.0% | 1:11 |
| Ashkenazi Jewish | 1:4 | 54.0% | 1:8 |
| Non-Ashkenazi Jewish | 1:4 | 69.0% | 1:11 |
| Turkish | 1:6 | 76.0% | 1:22 |
| Arab | 1:7 | 53.0% | 1:14 |

FANCONI ANEMIA

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------------|--------------|----------------|---------------|
| Ashkenazi Jewish | 1:89 | 99.0% | 1:8801 |

GALACTOKINASE DEFICIENCY

DATA NOT AVAILABLE

There is insufficient published data to determine the carrier rate, detection rate, and residual risk for this condition.

GALACTOSEMIA

Duarte Variant

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|-------------------|--------------|----------------|---------------|
| Northern European | 1:9 | 100.0% | 0 |
| Western European | 1:11 | 100.0% | 0 |
| Eastern European | 1:12 | 100.0% | 0 |
| Southern European | 1:18 | 100.0% | 0 |
| Asian | 1:56 | 100.0% | 0 |

Classic

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|-------------------|--------------|----------------|---------------|
| Northern European | 1:111 | 80.0% | 1:551 |
| Southern European | 1:234 | 80.0% | 1:1166 |
| Western European | 1:270 | 80.0% | 1:1346 |
| African American | 1:1010 | 80.0% | 1:5046 |
| Eastern European | 1:1016 | 80.0% | 1:5076 |

GAUCHER DISEASE

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------------|--------------|----------------|---------------|
| Ashkenazi Jewish | 1:18 | 90.0% | 1:171 |
| Pan-ethnic | 1:50 | 64.0% | 1:137 |

GLUTARIC ACIDEMIA, TYPE 1

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------|--------------|----------------|---------------|
| Caucasian | 1:159 | 38.0% | 1:256 |

GLYCOGEN STORAGE DISEASE, TYPE 1A

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------------|--------------|----------------|---------------|
| Ashkenazi Jewish | 1:71 | 93.0% | 1:1001 |
| Non-Jewish | 1:158 | 62.0% | 1:414 |

GLYCOGEN STORAGE DISEASE, TYPE IB

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------|--------------|----------------|---------------|
| European | 1:354 | 47.0% | 1:667 |
| Japanese | 1:354 | 50.0% | 1:707 |

GLYCOGEN STORAGE DISEASE, TYPE III

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------|--------------|----------------|---------------|
| General | 1:158 | 20.0% | 1:197 |

GLYCOGEN STORAGE DISEASE, TYPE V

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------|--------------|----------------|---------------|
| US general | 1:158 | 41.0% | 1:267 |
| Spanish | 1:206 | 41.0% | 1:348 |

GM1-GANGLIOSIDOSIS

DATA NOT AVAILABLE

There is insufficient published data to determine the carrier rate, detection rate, and residual risk for this condition.

HEARING LOSS, DFNB1 AND DFNB9 NONSYNDROMIC

DATA NOT AVAILABLE

There is insufficient published data to determine the carrier rate, detection rate, and residual risk for this condition.

HEARING LOSS, DFNB59 NONSYNDROMIC

DATA NOT AVAILABLE

There is insufficient published data to determine the carrier rate, detection rate, and residual risk for this condition.

HEMOCHROMATOSIS

HFE

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|-------------------|--------------|----------------|---------------|
| Northern European | 1:3 | 63.0% | 1:6 |

HFE2

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|-----------------|--------------|----------------|---------------|
| French-Canadian | 1:500 | 100.0% | Negligible |
| Greek | 1:500 | 70.0% | 1:1664 |
| Italian | 1:500 | 4.0% | 1:521 |

| | |
|-------------|----------------|
| PATIENT ID | SAMPLE PATIENT |
| GENDER | M |
| ACCESSION # | XXXXXXXX |
| REPORT DATE | Feb 27, 2017 |

HEMOGLOBIN C

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|-------------------|--------------|----------------|---------------|
| African American | 1:52 | 100.0% | 0 |
| Native American | 1:489 | 100.0% | 0 |
| Hispanic American | 1:1517 | 100.0% | 0 |
| Caucasian | 1:2754 | 100.0% | 0 |
| Asian Indian | 1:4768 | 100.0% | 0 |
| Filipino | 1:4775 | 100.0% | 0 |
| Middle Eastern | 1:5476 | 100.0% | 0 |
| Asian | 1:6607 | 100.0% | 0 |
| Southeast Asian | 1:14200 | 100.0% | 0 |

HEMOGLOBIN D

HbD-Punjab

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|-------------|--------------|----------------|---------------|
| South Asian | 1:232 | 100.0% | 0 |

HEMOGLOBIN E

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|---------------|--------------|----------------|---------------|
| Bangladeshi | 1:24 | 100.0% | 0 |
| Chinese | 1:221 | 100.0% | 0 |
| Pakistani | 1:529 | 100.0% | 0 |
| Asian Indian | 1:578 | 100.0% | 0 |
| White Irish | 1:1961 | 100.0% | 0 |
| White British | 1:9091 | 100.0% | 0 |
| African | 1:10000 | 100.0% | 0 |

HEMOGLOBIN O

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------------|--------------|----------------|---------------|
| South Asian | 1:233 | 100.0% | 0 |
| General | 1:1428 | 100.0% | 0 |
| African American | 1:30000 | 100.0% | 0 |

HEREDITARY FRUCTOSE INTOLERANCE

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------------|--------------|----------------|---------------|
| Middle Eastern | 1:97 | 50.0% | 1:193 |
| US general | 1:122 | 50.0% | 1:243 |
| African American | 1:226 | 50.0% | 1:451 |

HERLITZ JUNCTIONAL EPIDERMOLYSIS BULLOSA, LAMA3-RELATED

LAMA3, LAMB3, LAMC2

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------|--------------|----------------|---------------|
| US general | 1:781 | 45.0% | 1:1419 |

HERLITZ JUNCTIONAL EPIDERMOLYSIS BULLOSA, LAMB3-RELATED

LAMA3, LAMB3, LAMC2

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------|--------------|----------------|---------------|
| US general | 1:781 | 45.0% | 1:1419 |

HERLITZ JUNCTIONAL EPIDERMOLYSIS BULLOSA, LAMC2-RELATED

LAMA3, LAMB3, LAMC2

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------|--------------|----------------|---------------|
| US general | 1:781 | 45.0% | 1:1419 |

HMG-COA LYASE DEFICIENCY

DATA NOT AVAILABLE

There is insufficient published data to determine the carrier rate, detection rate, and residual risk for this condition.

HOMOCYSTINURIA, CBLE TYPE

DATA NOT AVAILABLE

There is insufficient published data to determine the carrier rate, detection rate, and residual risk for this condition.

HOMOCYSTINURIA, CLASSIC

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------|--------------|----------------|---------------|
| UK | 1:500 | 50.0% | 1:999 |
| US general | 1:500 | 26.0% | 1:675 |

HURLER SYNDROME

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------|--------------|----------------|---------------|
| Caucasian | 1:159 | 79.0% | 1:753 |

HYPOPHOSPHATASIA, AUTOSOMAL RECESSIVE

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------|--------------|----------------|---------------|
| Japanese | 1:194 | 41.0% | 1:328 |

| | |
|-------------|----------------|
| PATIENT ID | SAMPLE PATIENT |
| GENDER | M |
| ACCESSION # | XXXXXXX |
| REPORT DATE | Feb 27, 2017 |

INCLUSION BODY MYOPATHY 2

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|-----------------------|--------------|----------------|---------------|
| Middle Eastern Jewish | 1:15 | 100.0% | Negligible |
| Japanese | Unknown | 100.0% | Negligible |

JUVENILE RETINOSCHISIS, X-LINKED

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------|--------------|----------------|---------------|
| Finnish | 1:65 | 95.0% | 1:1281 |

KRABBE DISEASE

DATA NOT AVAILABLE

There is insufficient published data to determine the carrier rate, detection rate, and residual risk for this condition.

LIPOAMIDE DEHYDROGENASE DEFICIENCY

DATA NOT AVAILABLE

There is insufficient published data to determine the carrier rate, detection rate, and residual risk for this condition.

LIPOPROTEIN LIPASE DEFICIENCY, FAMILIAL

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------|--------------|----------------|---------------|
| Caucasian | 1:500 | 46.0% | 1:925 |

MAPLE SYRUP URINE DISEASE

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------------|--------------|----------------|---------------|
| Ashkenazi Jewish | 1:97 | 99.0% | 1:1921 |

MEDIUM-CHAIN ACYL-COA DEHYDROGENASE DEFICIENCY

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------|--------------|----------------|---------------|
| Caucasian | 1:40 | 70.0% | 1:131 |

MEGALENCEPHALIC LEUKOENCEPHALOPATHY WITH SUBCORTICAL CYSTS

DATA NOT AVAILABLE

There is insufficient published data to determine the carrier rate, detection rate, and residual risk for this condition.

METACHROMATIC LEUKODYSTROPHY

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------|--------------|----------------|---------------|
| Australian | 1:100 | 46.0% | 1:184 |
| Polish | 1:100 | 54.0% | 1:216 |

METHYLMALONIC ACIDEMIA

MUT

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------|--------------|----------------|---------------|
| Japanese | 1:187 | 22.0% | 1:239 |
| Black | 1:237 | 35.0% | 1:364 |
| Caucasian | 1:237 | 19.0% | 1:292 |
| Hispanic | 1:237 | 41.0% | 1:401 |

MMAA

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------|--------------|----------------|---------------|
| Japanese | 1:448 | 64.0% | 1:1243 |
| Caucasian | 1:568 | 43.0% | 1:996 |

MUCOLIPIDOSIS II

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|---------------------|--------------|----------------|---------------|
| Japanese | 1:500 | 60.0% | 1:1249 |
| Predominantly white | 1:500 | 56.0% | 1:1135 |

MUCOLIPIDOSIS III

DATA NOT AVAILABLE

There is insufficient published data to determine the carrier rate, detection rate, and residual risk for this condition.

MUCOLIPIDOSIS IV

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------------|--------------|----------------|---------------|
| Ashkenazi Jewish | 1:127 | 95.0% | 1:2521 |

MULTIPLE CARBOXYLASE DEFICIENCY

DATA NOT AVAILABLE

There is insufficient published data to determine the carrier rate, detection rate, and residual risk for this condition.

NEPHROTIC SYNDROME, STEROID-RESISTANT

DATA NOT AVAILABLE

There is insufficient published data to determine the carrier rate, detection rate, and residual risk for this condition.

NEURONAL CEROID LIPOFUSCINOSIS, CLN3-RELATED

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|-------------|--------------|----------------|---------------|
| Finnish | 1:70 | 85.0% | 1:461 |
| West German | 1:188 | 85.0% | 1:1248 |

| | |
|-------------|----------------|
| PATIENT ID | SAMPLE PATIENT |
| GENDER | M |
| ACCESSION # | XXXXXXX |
| REPORT DATE | Feb 27, 2017 |

NEURONAL CEROID LIPOFUSCINOSIS, CLN5-RELATED

DATA NOT AVAILABLE

There is insufficient published data to determine the carrier rate, detection rate, and residual risk for this condition.

NEURONAL CEROID LIPOFUSCINOSIS, CLN8-RELATED

DATA NOT AVAILABLE

There is insufficient published data to determine the carrier rate, detection rate, and residual risk for this condition.

NEURONAL CEROID LIPOFUSCINOSIS, PPT1-RELATED

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------|--------------|----------------|---------------|
| Finnish | 1:70 | 98.0% | 1:3451 |

NEURONAL CEROID LIPOFUSCINOSIS, TPP1-RELATED

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|----------------|--------------|----------------|---------------|
| Newfoundlander | 1:53 | 69.0% | 1:169 |

NIEMANN-PICK DISEASE

Type A

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------------|--------------|----------------|---------------|
| Ashkenazi Jewish | 1:90 | 97.0% | 1:2968 |

NIJMEGEN BREAKAGE SYNDROME

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|-------------------------|--------------|----------------|---------------|
| Eastern European Slavic | 1:155 | 100.0% | Negligible |
| North American | 1:158 | 70.0% | 1:524 |

PENDRED SYNDROME

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|-----------------------------|--------------|----------------|---------------|
| Chinese | 1:50 | 84.0% | 1:307 |
| Japanese | 1:50 | 53.0% | 1:105 |
| Northern European Caucasian | 1:60 | 50.0% | 1:119 |

PHENYLKETONURIA

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|-----------------|--------------|----------------|---------------|
| Irish | 1:34 | 72.0% | 1:119 |
| Turkish | 1:34 | 65.0% | 1:95 |
| French-Canadian | 1:45 | 56.0% | 1:101 |
| Polish | 1:45 | 78.0% | 1:201 |
| Spanish | 1:51 | 41.0% | 1:86 |
| Chinese | 1:53 | 54.0% | 1:114 |
| Danish | 1:55 | 43.0% | 1:96 |
| US Caucasian | 1:62 | 51.0% | 1:125 |
| Korean | 1:102 | 62.0% | 1:267 |
| Japanese | 1:174 | 70.0% | 1:578 |

POLYCYSTIC KIDNEY DISEASE

DATA NOT AVAILABLE

There is insufficient published data to determine the carrier rate, detection rate, and residual risk for this condition.

POMPE DISEASE

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|--------------------|--------------|----------------|---------------|
| African American | 1:59 | 60.0% | 1:146 |
| Dutch | 1:185 | 40.0% | 1:308 |
| Taiwanese, Chinese | 1:185 | 80.0% | 1:921 |

PREKALLIKREIN DEFICIENCY

DATA NOT AVAILABLE

There is insufficient published data to determine the carrier rate, detection rate, and residual risk for this condition.

PRIMARY HYPEROXALURIA, TYPE 1

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------|--------------|----------------|---------------|
| European | 1:173 | 44.0% | 1:308 |
| Worldwide | 1:289 | 44.0% | 1:515 |

PRIMARY HYPEROXALURIA, TYPE 2

DATA NOT AVAILABLE

There is insufficient published data to determine the carrier rate, detection rate, and residual risk for this condition.

PRIMARY HYPEROXALURIA, TYPE 3

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------|--------------|----------------|---------------|
| Worldwide | 1:913 | 75.0% | 1:3649 |

| | |
|-------------|----------------|
| PATIENT ID | SAMPLE PATIENT |
| GENDER | M |
| ACCESSION # | XXXXXXX |
| REPORT DATE | Feb 27, 2017 |

PROPIONIC ACIDEMIA

PCCA, PCCB

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------|--------------|----------------|---------------|
| Japanese | 1:160 | 35.0% | 1:246 |

PCCB

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|-------------------|--------------|----------------|---------------|
| Northern European | 1:160 | 30.0% | 1:228 |
| Spanish | 1:160 | 50.0% | 1:320 |

PROTHROMBIN DEFICIENCY

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------------|--------------|----------------|---------------|
| Iranian, Italian | 1:707 | 54.0% | 1:1536 |

RH-NULL SYNDROME

DATA NOT AVAILABLE

There is insufficient published data to determine the carrier rate, detection rate, and residual risk for this condition.

RHIZOMELIC CHONDRODYSPLASIA PUNCTATE TYPE 1

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------|--------------|----------------|---------------|
| Pan-ethnic | 1:158 | 51.0% | 1:321 |

RICKETS, PSEUDOVITAMIN D-DEFICIENCY

DATA NOT AVAILABLE

There is insufficient published data to determine the carrier rate, detection rate, and residual risk for this condition.

SALLA DISEASE

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|----------------------|--------------|----------------|---------------|
| Northeastern Finnish | 1:100 | 95.0% | 1:1981 |

SANDHOFF DISEASE

DATA NOT AVAILABLE

There is insufficient published data to determine the carrier rate, detection rate, and residual risk for this condition.

SHORT-CHAIN ACYL-COA DEHYDROGENASE DEFICIENCY

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------------|--------------|----------------|---------------|
| Ashkenazi Jewish | 1:15 | 65.0% | 1:41 |

SICK SINUS SYNDROME

DATA NOT AVAILABLE

There is insufficient published data to determine the carrier rate, detection rate, and residual risk for this condition.

SICKLE CELL DISEASE

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|-------------------|--------------|----------------|---------------|
| African American | 1:15 | 100.0% | 0 |
| Native American | 1:150 | 100.0% | 0 |
| Hispanic American | 1:203 | 100.0% | 0 |
| Middle Eastern | 1:478 | 100.0% | 0 |
| Caucasian | 1:642 | 100.0% | 0 |
| Asian Indian | 1:652 | 100.0% | 0 |
| Filipino | 1:879 | 100.0% | 0 |
| Asian | 1:1315 | 100.0% | 0 |
| Southeast Asian | 1:2365 | 100.0% | 0 |

SMITH-LEMLI-OPITZ SYNDROME

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|-----------------------|--------------|----------------|---------------|
| Northwestern European | 1:50 | 69.2% | 1:150 |
| General | 1:68 | 69.2% | 1:219 |
| Southern European | 1:83 | 69.2% | 1:267 |
| Middle Eastern | 1:129 | 69.2% | 1:417 |
| Hispanic | 1:135 | 69.2% | 1:436 |
| African American | 1:339 | 69.2% | 1:1098 |

SPHEROCYTOSIS, HEREDITARY

DATA NOT AVAILABLE

There is insufficient published data to determine the carrier rate, detection rate, and residual risk for this condition.

TAY-SACHS DISEASE

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------------|--------------|----------------|---------------|
| Ashkenazi Jewish | 1:31 | 99.0% | 1:3001 |
| Non-Jewish | 1:250 | 46.0% | 1:462 |

TAY-SACHS PSEUDODEFICIENCY

DATA NOT AVAILABLE

There is insufficient published data to determine the carrier rate, detection rate, and residual risk for this condition.

| | |
|-------------|----------------|
| PATIENT ID | SAMPLE PATIENT |
| GENDER | M |
| ACCESSION # | XXXXXXXX |
| REPORT DATE | Feb 27, 2017 |

THROMBOCYTOPENIA, CONGENITAL AMEGAKARYOCYTIC

DATA NOT AVAILABLE

There is insufficient published data to determine the carrier rate, detection rate, and residual risk for this condition.

TYROSINE HYDROXYLASE DEFICIENCY

DATA NOT AVAILABLE

There is insufficient published data to determine the carrier rate, detection rate, and residual risk for this condition.

TYROSINEMIA

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------------|--------------|----------------|---------------|
| French-Canadian | 1:66 | 87.0% | 1:501 |
| Ashkenazi Jewish | 1:100 | 99.0% | 1:9901 |
| US general | 1:150 | 60.0% | 1:374 |

USHER SYNDROME, TYPE 1F

DATA NOT AVAILABLE

There is insufficient published data to determine the carrier rate, detection rate, and residual risk for this condition.

VERY LONG-CHAIN ACYL-COA DEHYDROGENASE DEFICIENCY

DATA NOT AVAILABLE

There is insufficient published data to determine the carrier rate, detection rate, and residual risk for this condition.

VON WILLEBRAND DISEASE, TYPE 2 NORMANDY

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------|--------------|----------------|---------------|
| Pan-ethnic | 1:500 | 75.0% | 1:1997 |

VON WILLEBRAND DISEASE, TYPE 3

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------------|--------------|----------------|---------------|
| Swedish, Finnish | 1:500 | 10.0% | 1:555 |

WILSON DISEASE

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------|--------------|----------------|---------------|
| Asian | 1:90 | 57.0% | 1:208 |
| European | 1:90 | 35.0% | 1:138 |

ZELLWEGER SYNDROME SPECTRUM, PEX1-RELATED

| POPULATION | CARRIER RATE | DETECTION RATE | RESIDUAL RISK |
|------------|--------------|----------------|---------------|
| Pan-ethnic | 1:147 | 80.0% | 1:731 |

TEST METHODOLOGY

Genotyping by PCR-based enrichment and next-generation sequencing.

RESULT STATUS DEFINITIONS

Final



Test results that are available at the time of report issue or have been revised from pending status to final status.